Autonomix Medical (Nasdaq:AMIX) announced that it received a new patent titled controlled sympathectomy and micro-ablation systems and methods. U.S. Patent No. 12,257,071 (‘071 patent) relates to advanced catheter-based systems that combine nerve mapping and radiofrequency (RF) ablation. The technologies provide enhanced precision in treating … [Read more...] about Autonomix picks up key nerve ablation catheter patent
Autonomix
Autonomix secures U.S. patent for cancer-treating tech
Autonomix this week announced it received a patent from the U.S. Patent and Trademark Office (USPTO) for its catheter-based cancer tumor treating technology. The patent, titled Systems and Methods for Treating Cancer and/or Augmenting Organ Function, covers the company technology, including systems, methods, and devices for interventionally … [Read more...] about Autonomix secures U.S. patent for cancer-treating tech
Nerve ablation tech developer Autonomix to effect a reverse stock split
Autonomix (Nasdaq:AMIX) announced today that it filed to effect a 1-for-20 reverse stock split of its common stock. The Woodlands, Texas-based Autonomix plans for the split to take effect at 11:59 p.m. ET on Oct. 24, 2024. It plans for its common stock to open trading on the Nasdaq market on Oct. 25, 2024, on a post-split basis, under the … [Read more...] about Nerve ablation tech developer Autonomix to effect a reverse stock split